Endoscopic submucosal dissection for visible dysplasia in IBD: A nationwide multicenter cohort from the GETAID and the SFED

Abstract Background and aims New techniques for endoscopic resection, including endoscopic submucosal dissection (ESD), have been developed to allow for en-bloc resection with very low recurrence rates and organ sparing in patients without inflammatory bowel disease (IBD). Data on ESD for the management of colorectal dysplasia in IBD patients are scarce. We aimed to evaluate the efficacy and safety of ESD for the treatment of IBD. Methods We conducted a retrospective multicenter cohort study that evaluated consecutive ESD procedures in IBD patients with visible dysplasia from 20 French centers with ESD experience. Between June 2008 and March 2022, all IBD patients included in the local ESD databases and who underwent ESD for visible dysplasia proven on biopsy, were included. All patients were included from the date ESD was performed, and endoscopic follow-up and surgical data were collected. Results Among the 88 lesions resected in 82 patients (19 patients with Crohn’s disease (CD)), 82% and 80% of patients had R0 and curative resection respectively. Ten (12%) patients required surgery: one for complication, 3 for endoscopic failure and 6 for noncurative resection. After a median follow-up of 20 (IQR 10,5-45) months, 4 patients experienced local recurrence, and 14 (17%) underwent surgery. Two patients died from cardiovascular issues during the follow-up. Factors associated with local recurrence were R1 resection, associated primary sclerosing cholangitis, a personal history of colorectal cancer and active lesions at the ESD site. Conclusion ESD is feasible for IBD patients with visible colorectal dysplasia and has an acceptable safety profile. These findings should be evaluated further in control trials.